|Day Low/High||53.15 / 53.71|
|52 Wk Low/High||46.01 / 77.12|
Jim Cramer looks at how the French elections are smacking the U.S stock markets. Plus, he has the week-ahead game plan for oil and stocks.
Bristol-Myers Squibb Company (NYSE:BMY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Opdivo (nivolumab) for the...
Consider this BMY bullishly biased, near-the-money vertical call spread.
Bristol-Myers Squibb Company (NYSE:BMY) and Nordic Bioscience, a Danish company specializing in biomarker technologies, today announced a collaboration agreement to develop biomarker technology to potentially aid in...
Doug Kass shares his thoughts on Apple, Allergan and Western Digital.
Synergy Pharmaceuticals, Biogen and Insys Therapeutics were among the biotech stock movers in premarket trading on Thursday.
Biogen (NASDAQ:BIIB) today announced an agreement to exclusively license BMS-986168, a Phase 2-ready experimental medicine with potential in Alzheimer's disease (AD) and progressive supranuclear palsy (PSP), from...
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for Progressive Supranuclear Palsy (PSP), to...
Eli Lilly has become the new go-to name in the pharmaceutical space, even over Johnson & Johnson, Cramer said.
Bristol-Myers Squibb Company (NYSE:BMY) and Apexigen, Inc.
The activist investor launched an insurgency campaign at the organic grocer, seeking to press the company to consider strategic options and make other share-price improving changes.
'These companies are all assessing the Trump effect,' Cramer said.
Incyte has been doing great, locking in deals with Bristol-Myers and Merck. It's worth a lot more in a takeover situation, Cramer said.
The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.
The biotechnology sector is enjoying robust recovery, driving Big Pharma shares to lofty levels. But this biotech stalwart is a great value play now.
Jim Cramer says what's more noteworthy than the pullback is the day's strong rebound.
It's pretty normal to have profit-taking after such a strong first quarter.
Bristol-Myers Squibb Company (NYSE:BMY) today announced that CheckMate -143, a randomized Phase 3 clinical trial evaluating the efficacy and safety of Opdivo in patients with first recurrence of glioblastoma multiforme...
Bristol-Myers Squibb Company (NYSE:BMY) today announced the first overall survival (OS) data from the Phase 3 CheckMate -067 clinical trial.
Bristol-Myers Squibb Company (NYSE:BMY) today announced the first report of five-year overall survival (OS) data from the Phase 1 dose-ranging study CA209-003 evaluating Opdivo in patients with previously treated...
The broad development plan across five different types of cancer widens Incyte's lead over other IDO inhibitors in clinical development.
We know that we are in the era when index managers are ascendant.
Bristol-Myers Squibb Company (NYSE:BMY) and Incyte Corporation (Nasdaq:INCY) today announced the companies have agreed to advance their clinical development program evaluating the combination of epacadostat,...
Bristol-Myers Squibb Company (NYSE:BMY) and Foundation Medicine (NASDAQ:FMI) today announced a collaboration that leverages Foundation Medicine's comprehensive genomic profiling and molecular information solutions...
The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb Company (NYSE: BMY) and the Cancer Research Institute (CRI) today announced a multi-year clinical research collaboration to coordinate and rapidly...